US 11,969,534 B2
Blood treatment device priming devices, methods, and systems
James M. Brugger, Newburyport, MA (US); and David Desouza, Essex, MA (US)
Assigned to NxStage Medical, Inc., Lawrence, MA (US)
Filed by NxStage Medical, Inc., Lawrence, MA (US)
Filed on May 5, 2023, as Appl. No. 18/143,733.
Application 17/218,860 is a division of application No. 16/366,714, filed on Mar. 27, 2019, granted, now 10,987,461, issued on Apr. 27, 2021.
Application 16/366,714 is a division of application No. 15/564,719, granted, now 10,279,098, issued on May 7, 2019, previously published as PCT/US2016/026525, filed on Apr. 7, 2016.
Application 18/143,733 is a continuation of application No. 17/218,860, filed on Mar. 31, 2021, granted, now 11,679,190.
Claims priority of provisional application 62/298,620, filed on Feb. 23, 2016.
Claims priority of provisional application 62/143,880, filed on Apr. 7, 2015.
Prior Publication US 2023/0302212 A1, Sep. 28, 2023
Int. Cl. A61M 1/36 (2006.01); A61M 39/10 (2006.01)
CPC A61M 1/3643 (2013.01) [A61M 1/3629 (2014.02); A61M 1/3644 (2014.02); A61M 1/3646 (2014.02); A61M 1/3652 (2014.02); A61M 1/3672 (2013.01); A61M 39/10 (2013.01); A61M 2205/3331 (2013.01); A61M 2205/702 (2013.01); A61M 2205/705 (2013.01); A61M 2205/707 (2013.01)] 10 Claims
 
1. A method of performing a blood treatment without an anticoagulant, comprising:
initiating an extracorporeal blood treatment employing an initial blood treatment device, the blood treatment employing no anticoagulant;
passing blood through the initial blood treatment device and observing one or more indicators of a blood treatment device-clogging trend;
determining that the initial blood treatment device may need to be replaced responsively to said one or more indicators;
priming a replacement blood treatment device;
determining that the initial blood treatment device should be replaced responsively to said one or more indicators;
replacing the initial blood treatment device with the replacement blood treatment device primed by said priming; and
thereafter, continuing the extracorporeal blood treatment and observing so as to avoid the need for the anticoagulant.